As expected, Level 1 alterations, defined as FDA-recognized biomarkers for response to an FDA-approved drug, were most frequent in GIST due to KIT and PDGFRA mutations (Fig. 6A). The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.